Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report

Jeremy Sugarman; Roger A. Barker; Ian Kerridge; Tamra Lysaght; Graziella Pellegrini; Douglas Sipp; Claire Tanner

doi:10.1016/j.stemcr.2018.10.020

Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report

Jeremy Sugarman, Roger A. Barker, Ian Kerridge, Tamra Lysaght, Graziella Pellegrini, Douglas Sipp, Claire Tanner

Research output: Contribution to journal › Article › Other › peer-review

13 Citations (Scopus)

Abstract

Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.

Original language	English
Pages (from-to)	1021-1025
Number of pages	5
Journal	Stem Cell Reports
Volume	11
Issue number	5
DOIs	https://doi.org/10.1016/j.stemcr.2018.10.020
Publication status	Published - 13 Nov 2018
Externally published	Yes

Access to Document

10.1016/j.stemcr.2018.10.020

Cite this

@article{e2359640ff0f4df8a5d66440b526a55f,

title = "Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report",

abstract = "Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.",

author = "Jeremy Sugarman and Barker, {Roger A.} and Ian Kerridge and Tamra Lysaght and Graziella Pellegrini and Douglas Sipp and Claire Tanner",

year = "2018",

month = nov,

day = "13",

doi = "10.1016/j.stemcr.2018.10.020",

language = "English",

volume = "11",

pages = "1021--1025",

journal = "Stem Cell Reports",

issn = "2213-6711",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies

T2 - ISSCR 2018 Annual Meeting Focus Session Report

AU - Sugarman, Jeremy

AU - Barker, Roger A.

AU - Kerridge, Ian

AU - Lysaght, Tamra

AU - Pellegrini, Graziella

AU - Sipp, Douglas

AU - Tanner, Claire

PY - 2018/11/13

Y1 - 2018/11/13

N2 - Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.

AB - Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.

UR - http://www.scopus.com/inward/record.url?scp=85055877161&partnerID=8YFLogxK

U2 - 10.1016/j.stemcr.2018.10.020

DO - 10.1016/j.stemcr.2018.10.020

M3 - Article

C2 - 30428384

AN - SCOPUS:85055877161

SN - 2213-6711

VL - 11

SP - 1021

EP - 1025

JO - Stem Cell Reports

JF - Stem Cell Reports

IS - 5

ER -

Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report

Abstract

Access to Document

Other files and links

Cite this